Merck (MRK) Other financing activities (2009 - 2026)
Merck (MRK) posted quarterly Other financing activities of -$80.0 million for Q1 2026, down 521.05% year-over-year from $19.0 million in Q1 2025, and down 270.21% quarter-over-quarter from $47.0 million in Q4 2025.
Merck (MRK) Other financing activities (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Other financing activities for 18 consecutive years, with -$80.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 521.05% year-over-year to -$80.0 million; the TTM figure through Mar 2026 stood at -$7.0 million (up 98.41% YoY), while the FY2025 annual figure was $92.0 million, up 124.73% from the prior year.
- Other financing activities slipped to -$80.0 million in Q1 2026 per MRK's latest filing, from $47.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $434.0 million in Q3 2023 and bottomed at -$447.0 million in Q4 2023.
- Historically, Other financing activities has averaged -$54.6 million across 5 years, with a median of -$68.0 million in 2022.
- Annual changes were most pronounced in 2022 — Other financing activities sank 1244.44% — and 2025, when it surged 1034.38%.
- Merck's Other financing activities stood at -$68.0 million in 2022, then tumbled by 557.35% to -$447.0 million in 2023, then surged by 90.6% to -$42.0 million in 2024, then soared by 211.9% to $47.0 million in 2025, then slumped by 270.21% to -$80.0 million in 2026.
- Business Quant data shows MRK's Other financing activities at -$80.0 million in Q1 2026, $47.0 million in Q4 2025, and $299.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -507.00 Mn |
| Jun 30, 2026 | -507.00 Mn |
| Mar 31, 2026 | -80.00 Mn |
| Mar 31, 2026 | -80.00 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Sep 30, 2025 | 299.00 Mn |
| Sep 30, 2025 | 299.00 Mn |
| Jun 30, 2025 | -273.00 Mn |
| Jun 30, 2025 | -273.00 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Dec 31, 2024 | -42.00 Mn |
| Dec 31, 2024 | -42.00 Mn |
| Sep 30, 2024 | -32.00 Mn |
| Sep 30, 2024 | -32.00 Mn |
| Jun 30, 2024 | -385.00 Mn |
| Jun 30, 2024 | -385.00 Mn |
| Mar 31, 2024 | 87.00 Mn |
| Mar 31, 2024 | 87.00 Mn |